David Fabrizio
Vice President, Commercial Strategy & Medical Innovation Foundation Medicine
Seminars
Tuesday 21st July 2026
Redefining the Standard in MRD: Leveraging SVs & dPCR to Deliver Ultra-Sensitivity & High Specificity
9:00 am
- Introduce the first and only MRD assay to combine the reliability of structural variants with the speed of digital PCR
- Showcase data illustrating the assay’s sensitivity, specificity, and accelerated turnaround time
- Highlight how established global infrastructure can enable patient access worldwide
*FoundationOne®MRD is performed by SAGA Diagnostics US, Inc. and has not been cleared or approved by the FDA.
